The history of strategic planning research as a foundation for the specific study of the strategic planning process in the US pharmaceutical industry is presented. A complete literature review is also provided. The economic variables that directly effect the US pharmaceutical industry: profitability, risk, research and development, promotion, federal regulation, and the generic drug sector of the drug industry are discussed. With this foundation, a short discussion of studies directly related to strategic planning in the US pharmaceutical industry and potential areas for future research are also suggested.
BrownJSandsSThompsonGC.Long range planning in the U.S.A.-NICB. Long Range Planning.1969;1(3):44–51.
14.
AugJChuaJ.Long range planning in large United States corporations. Long Range Planning.1979;12(3):99–102.
15.
AnsoffHIAvenerJBrandenburgRDoes planning pay? The effect of planning on success and acquisition in American firms. Long Range Planning.1970;3(2):2–7.
16.
ThuneSHouseR.Where long range planning pays off. Business Horizons.1970;13:81–87.
17.
KudlaR.Strategic planning and risk. Review of Business & Economic Research.1981;17(1):2–14.
18.
LeontiadesMTezelA.Planning perceptions and planning results. Strategic Management Journal.1980;1(1):65–70.
19.
GreenlyG.Does strategic planning improve company performance?Long Range Planning.1986;19(2):101–109.
20.
MalikZKargerD.Does long range planning improve company performance?Management Review.1975;64(9):27–31.
21.
RingbakkK.Why planning fails. European Business (Spring 1971).
22.
SteinerG.Pitfalls in comprehensive long range planning. Oxford, OH: Planning Executives Institute; 1972.
23.
SteinerGSchollhammerH.Pitfalls of multinational long-range planning. Long Range Planning.1975;8(2):2–7.
24.
ShettyYK.New look at corporate goals. California Management Review.1979;22(2):74.
25.
AlexanderLD.Successfully implementing strategic decisions. Long Range Planning.1985;18(3):91–97.
26.
StiweniusO.Planning for a rapidly changing environment in SAS. Long Range Planning.1985;18(2):22–29.
27.
EngledowJLenzRT.Whatever happened to environmental analysis. Long Range Planning.1985;18(2):93–106.
28.
DerkinderenFCrumR.Pitfalls in using portfolio techniques — Assessing risks and potential. Long Range Planning.1984;17(2):129–136.
29.
JainS.Environmental scanning in U.S. corporations. Long Range Planning.1984;17(2):117–128.
30.
FaheyLKingW.Environmental scanning for corporate planning. Business Horizons.1977;20(4):61–71.
31.
DiffenbachJ.Corporate environmental analysis in large corporations. Long Range Planning.1983;16(3):107–116.
32.
PorterM.Competitive strategy. New York: The Free Press; 1980.
33.
ByarsL.The strategic management process: A model & terminology. Managerial Planning.1984;32(6):38–44.
34.
HansenR.The pharmaceutical development process: Estimates of current development costs and times and the effect of regulatory changes. In: ChienRobert I., ed. Issues in Pharmaceutical Economics. Lexington, MA: D.C. Heath; 1979:151–181.
35.
ConradGPlotkinI.Risk/return: U.S. industry pattern. Harvard Business Review.1968;46:90–99.
SchartzmanD.Innovation in the pharmaceutical industry. Baltimore: Johns Hopkins University Press; 1976.
38.
Research & development in industry. Washington, D.C: National Science Foundation; 1982.
39.
LefflerK.Persuasion or information? The economics of prescription drug advertising. Journal of Law & Economics.1981;24(1):52.
40.
EganJHigginbothanHWestonF.Economics of the pharmaceutical industry.New York: Praeger, 1982.
41.
ComanorW.The political economy of the pharmaceutical industry. Journal of Economic Literature.1986;24(3):1196.
42.
PMAs 25 Largest Members Are Spending 20% of Annual Sales for Drug Research and Development, Rep.Waxman's Staff Reports on Drug Prices Finds. FDC Reports.1987;49(17):8–10.
43.
PradhanS.International pharmaceutical marketing. Westport, CT: Quorum Books; 1983.
44.
WaltonH.Ad recognition and prescribing by physicians. Journal of Advertising Research.1980;20(3):46.
45.
ComanorWWilsonT.Competition in the pharmaceutical industry. In: ChienR. I. ed. Issues in Pharmaceutical Economics.Lexington, MA: D.C. Heath, 1979.
46.
CooperM.Prices and profits in the pharmaceutical industry. London: Pergamon Press; 1966.
47.
HuttPMorrisonJ.Abbreviated new drug applications. Washington, D.C: Law & Business, Inc./Harcourt Brace Jovanovich, Publisher; 1985.
48.
Generic ANDA Deluge Set Off by Waxman Law, Drug & Cosmetic Industry.1985;136(1):42–45.
49.
Predicasts Forecasts.1989; Cleveland, OH., p. B255.
